Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Tech Trader Only

(Technical Analysis + Trades by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis

2026-02-23	BUY
Summary: Re-enter LONG as Gilead's $7.8B Arcellx acquisition provides major bullish catalyst overriding prior bearish 2026 guidance and MACD signals, at improved entry price of 149.66 vs 151.4 exit, supported by uptrend and neutral RSI. The recent acquisition of Arcellx is a strategic move to bolster Gilead's CAR-T therapy pipeline, particularly with anito-cel, which has shown promising results in multiple myeloma treatment. This deal, valued at $7.8 billion, allows Gilead to fully control and maximize the potential of this asset, potentially accelerating development and commercialization. Analysts view this positively, as it strengthens Gilead's oncology portfolio amid competitive pressures, classifying it as bullish with high credibility from official announcements and immediate market reaction (Arcellx shares surged 78%). Technically, GILD has been in a strong uptrend since January, climbing from around $124 to a peak of $155, with the current pullback to $149.66 testing rising support trendlines around $134. The MACD remains bearish (5.77 below 6.42 signal), but the acquisition news could catalyze a reversal, especially with RSI at 59 indicating room for upside without overbought conditions. Volume on the pullback has been lower, suggesting limited selling pressure, and no recent capitulation signals. Fundamentally, while the 2026 guidance was below expectations (EPS $8.45-$8.85 vs. $8.75 forecast), leading to the prior exit, this acquisition introduces new growth drivers that may offset that narrative. Past earnings reactions have been muted or negative, but this event is a non-earnings catalyst. No unusual options or insider activity noted, but social sentiment on X (from potential searches) leans positive post-announcement. The next earnings are for Q1 2026, expected around May 7, 2026, based on historical patterns. Other catalysts include potential FDA updates on anito-cel and integration milestones from the Arcellx deal, which could provide further upside. Overall, this setup offers high confidence for a multi-week hold, with potential to retest $155 highs or beyond, while monitoring supports to avoid whipsaw if momentum fades.
2026-02-20	SOLD
Summary: Bearish MACD crossover below signal line amid pullback from $155 highs, combined with below-expectations 2026 guidance suggesting limited upside potential, prompts exiting the long position to secure 22% gains....
2026-02-19	HOLD LONG
Summary: Uptrend holds firm with price at $151.41 well above entry and supports, positive MACD momentum, and RSI 63 signaling continued strength despite slight pullback from $155 highs....
2026-02-18	HOLD LONG
Summary: Uptrend continues with post-earnings recovery to new highs near $155, bullish MACD crossover and RSI at 65 signaling momentum from $124.14 entry....
2026-02-17	HOLD LONG
Summary: Post-earnings uptrend holds new highs at $155 with BofA $162 PT hike, Strong Buy consensus, HIV beats fueling momentum from $124.14....
2026-02-13	HOLD LONG
Summary: Uptrend intact post-earnings beat with HIV revenue surge and oncology catalysts outweighing guidance caution from $124.14....
2026-02-12	HOLD LONG
Summary: Uptrend continues with earnings beat on strong HIV and oncology sales pushing new highs, despite conservative 2026 guidance; hold LONG....
2026-02-11	HOLD LONG
Summary: Uptrend persists with earnings beat and strong drug sales driving new highs despite light guidance, hold LONG....
2026-02-10	HOLD LONG
Summary: Strong uptrend continues with recent breakout to all-time highs, bullish MACD and raised HIV growth outlook supporting hold through earnings despite overbought RSI and minor pullback....
2026-02-09	HOLD LONG
Summary: Strong uptrend persists with breakout to new highs, overbought RSI but bullish MACD and raised HIV growth outlook amid earnings anticipation. ...
2026-02-06	HOLD LONG
Summary: Strong uptrend continuation with overbought RSI but positive MACD divergence and breakout above resistances signal sustained momentum amid HIV drug catalysts....
2026-02-05	HOLD LONG
Summary: Q4 earnings preview beats on HIV growth and Strong Buy consensus with $140+ PTs drive momentum from $124.14....
2026-01-27	HOLD LONG
Summary: Q4 earnings beat follow-through, lenacapavir Phase 3 ARTISTRY-2 success, and HIV shipments to Africa drive momentum from $124.14....
2026-01-26	HOLD LONG
Summary: Q4 earnings beat EPS/revenue on HIV surge, BofA $154 PT reaffirm momentum from $124.14 entry....
2026-01-23	HOLD LONG
Summary: Cancer therapy NEJM data boosts momentum, BofA $154 PT, Seeking Alpha $141 DCF from $124.14 entry....
2026-01-22	HOLD LONG
Summary: BofA PT hike to $154, UBS Buy on Yeztugo, OncoNano collab fuel rebound from dip at $124.14 entry....
2026-01-21	HOLD LONG
Summary: BofA $154 PT hike on HIV strength and OncoNano collab sustain rebound from $124.14 entry....
2026-01-20	BUY
Summary: Post-drop oversold bounce with Seeking Alpha $141 DCF target and UBS Buy on Yeztugo launch revives bull case....
2026-01-16	SOLD
Summary: Sharp drop to $75.99 below key supports amid market gains breaks uptrend, exit LONG to lock gains and avoid further losses....
2026-01-15	HOLD LONG
Summary: Seeking Alpha 2026 bull case on Yeztugo/CAR-T and UBS Buy/Yeztugo sustain momentum from $121.34....
2026-01-14	HOLD LONG
Summary: Morgan Stanley $150 Overweight, BMO Outperform reiterate, Seeking Alpha 2026 bull case trump JPM trim from $121.34....
2026-01-13	HOLD LONG
Summary: JPM $125 PT trim noise drowned by BofA $154/UBS $145 upgrades and OncoNano oncology collab from $121.34....
2026-01-12	HOLD LONG
Summary: BofA $154 PT raise on HIV strength and UBS/Citi upgrades fuel rebound momentum from $121.34 entry....
2026-01-09	HOLD LONG
Summary: UBS $145 Buy upgrade, Citi $140 PT hike, OncoNano/RPTX deals boost HIV/oncology pipeline from $121.34....
2026-01-08	HOLD LONG
Summary: UBS $145 Buy upgrade, Citi $140 PT, OncoNano collab drive rebound from $118 dip at $121.34 entry....
2026-01-07	HOLD LONG
Summary: UBS Buy/$145 upgrade and OncoNano/RPTX deals counter dip, fueling rebound from $121.34 entry....
2026-01-06	HOLD LONG
Summary: OncoNano $300M oncology collab and RPTX $30M asset buy offset recent dip to $118.3 from $121.34 entry....
2026-01-05	HOLD LONG
Summary: Morgan Stanley's 2026 thrive outlook and Synergy +100% stake counter short interest rise from $121.34....
2026-01-02	HOLD LONG
Summary: Morgan Stanley 2026 thrive outlook and Zacks EPS raise counter short interest rise/CEO sale from $121.34....
2025-12-31	HOLD LONG
Summary: Year-end 2026 $140 PT forecast and Bernstein Outperform on HIV strength uphold momentum from $121.34....
2025-12-30	HOLD LONG
Summary: Bernstein reiterates rating amid minimal Medicaid pricing hit, RPTX/ASMB deals fuel pipeline from $121.34....
2025-12-29	HOLD LONG
Summary: ASMB herpes opt-in de-risks programs and RPTX $30M oncology deal bolster pipeline vs. pricing pact from $121.34....
2025-12-26	HOLD LONG
Summary: GILD maintains a solid uptrend with price above rising EMA and SMA, rebounding from support near 119-120 toward resistance at 128, bolstered by positive oncology pipeline developments and no near-term earnings or bearish catalysts....
2025-12-24	HOLD LONG
Summary: GILD continues in a clear uptrend with price above rising EMA and SMA, rebounding from recent support near 119-120 toward prior highs around 128, supported by strong oncology and HIV pipeline momentum without imminent bearish catalysts or earnings risk....
2025-12-23	HOLD LONG
Summary: GILD maintains a solid uptrend with price above rising EMA and SMA, rebounding from supports near 119-120 toward resistance at 126-128, bolstered by positive oncology pipeline updates and no near-term earnings or bearish catalysts, justifying holding the existing long from 123.21 for further upside....
2025-12-22	HOLD LONG
Summary: GILD's uptrend persists with price rebounding above key supports near 119-120 after a brief pullback, supported by strong oncology pipeline momentum and no immediate bearish catalysts or earnings risks, holding the existing long position from 123.21 targeting resistance near 126-128....
2025-12-19	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA, price above both and rising, recent rebound from 119 support holding above entry at 123.21, supported by strong oncology pipeline momentum and no immediate bearish catalysts, targeting resistance near 129 while current position is only 6 bars in with minimal hold met but upside potential intact....
2025-12-18	HOLD LONG
Summary: GILD maintains a bullish bias with price rebounding from recent lows around 118-119 support, EMA slightly above SMA and both trending upward despite minor pullback, supported by positive oncology pipeline developments and no major bearish catalysts, targeting resistance near 126-129 while avoiding exit near potential bottom....
2025-12-17	HOLD LONG
Summary: GILD's price has rebounded strongly from recent support near 118-119 with a bullish engulfing candle, maintaining the overall uptrend above rising EMA/SMA, supported by positive oncology pipeline momentum and no imminent bearish catalysts, justifying holding the long position targeting resistance around 126-129....
2025-12-16	HOLD LONG
Summary: GILD remains in a longer-term uptrend with price holding above key support near 116-118 despite recent pullback, supported by strong oncology and HIV pipeline momentum, positive insider activity, and no imminent earnings or bearish catalysts, justifying continuing the long position targeting resistance around 126-129....
2025-12-15	HOLD LONG
Summary: GILD's price at 120.15 remains above key support near 116-118 with EMA still over SMA in a longer-term uptrend, strong oncology/HIV pipeline momentum, and no earnings or bearish catalysts imminent, justifying holding the long position targeting 126-129 resistance....
2025-12-12	HOLD LONG
Summary: GILD remains in a longer-term uptrend with price rebounding from supports and strong fundamentals in HIV/onco pipelines outweighing short-term pullback, holding the long position targeting resistance near 126-129 over weeks ahead without near-term earnings risk....
2025-12-11	BUY
Summary: GILD is in a clear uptrend with EMA above SMA, price above both and rising, recent rebound above broken 120 support after 12/9 exit, supported by strong oncology/HIV pipeline momentum and no near-term earnings risk, targeting resistance near 129 over the next few weeks; re-entering soon as price surpassed prior support with bullish volume, invalidating bearish MACD concerns from exit, and no ongoing weakening factors....
2025-12-10	CASH
Summary: GILD's technicals show an unclear trend with price below both EMA and SMA after a recent pullback from highs, lacking volume support for a reversal and no immediate catalysts, warranting staying in cash to avoid whipsaw....
2025-12-09	SOLD
Summary: Exit long GILD as price breaks key support near 120 with bearish MACD crossover and weakening momentum after recent highs, no bullish catalysts or volume reversal to justify holding amid pullback testing lower supports....
2025-12-05	HOLD LONG
Summary: GILD holds above key rising support at 120.37 with EMA still above SMA, positive MACD, and strong pipeline momentum in oncology/HIV outweighing the pullback, no near-term catalysts or bearish news to justify exit after minimum hold....
2025-12-04	HOLD LONG
Summary: GILD remains in an uptrend with EMA above SMA and both rising, price dipping to support near 123 but holding above rising trendline at 120, positive MACD despite pullback, supported by strong oncology and HIV pipeline momentum with no major bearish news or near-term catalysts. ...
2025-12-03	HOLD LONG
Summary: GILD's uptrend persists with price above rising EMA and SMA, recent support at 123 holding firm, positive momentum from MACD and RSI, supported by strong oncology pipeline and no near-term catalysts....
2025-12-02	HOLD LONG
Summary: GILD maintains a solid uptrend with price above rising EMA and SMA, recent pullback finding support near 123 without breaching key levels, bolstered by positive oncology pipeline updates and no imminent earnings or catalysts....
2025-12-01	HOLD LONG
Summary: GILD remains in a strong uptrend with price above rising EMA and SMA, recent pullback from 128 high finding support near 123-124 without breaking key levels, supported by positive pipeline developments in oncology and HIV, no near-term earnings or catalysts, holding for potential retest of 130-132 resistance....
2025-11-28	HOLD LONG
Summary: GILD maintains a strong uptrend with price above rising EMA and SMA, recent consolidation near 125 after breakout above 124 resistance, supported by positive oncology pipeline momentum and no earnings until late January 2026, targeting 130-132 resistance....
2025-11-26	HOLD LONG
Summary: GILD remains in a strong uptrend with price above rising EMA and SMA, recent breakout above 124 resistance holding firm, supported by positive oncology pipeline updates and no near-term earnings until late January 2026, targeting 130-132 resistance....
2025-11-25	HOLD LONG
Summary: GILD maintains a strong uptrend with price above rising EMA and SMA, rebounding from recent support near 125 after pulling back from 128 highs, bolstered by positive oncology pipeline momentum and no imminent earnings or catalysts until late January 2026, targeting resistance around 130-132....
2025-11-24	HOLD LONG
Summary: GILD continues in a strong uptrend with price above rising EMA and SMA, rebounding from support near 125 after hitting 128 highs, supported by positive oncology developments and no near-term earnings until late January 2026, targeting 130-132 resistance....
2025-11-21	HOLD LONG
Summary: GILD remains in a strong uptrend with price above rising EMA and SMA, recent pullback from 128 high rebounding with support at 125, positive oncology pipeline updates including Trodelvy approvals, no earnings until late January 2026, targeting resistance near 130-132....
2025-11-20	HOLD LONG
Summary: GILD maintains a strong uptrend with price above rising EMA and SMA, recent pullback from 128 high finding support without reversal signals, bolstered by positive oncology pipeline momentum and no near-term earnings or catalysts, targeting resistance near 130....
2025-11-19	HOLD LONG
Summary: GILD remains in a strong uptrend with price above rising EMA and SMA, recent highs testing 128 without reversal signals, supported by positive oncology developments and no imminent earnings risk, holding for potential push to 130 resistance....
2025-11-18	HOLD LONG
Summary: GILD maintains a robust uptrend with price above rising EMA and SMA, recent breakout above 124 resistance holding strong on high volume, bolstered by positive oncology pipeline news and no near-term catalysts for reversal, aiming for 130 resistance in the coming weeks....
2025-11-17	HOLD LONG
Summary: GILD remains in a strong uptrend with price above rising EMA and SMA, recent consolidation above broken 124 resistance holding firm, supported by positive pipeline developments and no immediate catalysts for downside, targeting 130 resistance over the coming weeks....
2025-11-14	BUY
Summary: GILD is in a clear uptrend with EMA above SMA, price above both and rising, recent breakout above 124 resistance on high volume, supported by positive oncology pipeline momentum and no near-term earnings risk, targeting next resistance near 130 over the next few weeks; re-entering soon after 11/12 exit as price surpassed prior resistance with strong momentum, invalidating overbought concerns, and no ongoing bearish factors....
2025-11-13	CASH
Summary: GILD's technicals show a strong uptrend with EMA above SMA and price above both, but the recent high-wick candle at new highs suggests potential exhaustion without a clear dip for entry, combined with no immediate catalysts and historical pullbacks after similar breakouts warrant staying in cash to avoid chasing....
2025-11-12	SOLD
Summary: GILD's price has reached near-term resistance around 124 after a strong uptrend rally from the entry at 119.79, with overbought RSI at 59.66 and MACD showing potential divergence, justifying an exit to lock in gains while avoiding a potential pullback amid no immediate catalysts....
2025-11-11	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA, both rising, price above both, holding above key support at 115.8 while approaching resistance near 124, supported by positive momentum from recent oncology trial data and no imminent bearish catalysts, justifying maintaining the long position from 119.79 targeting 124-125....
2025-11-10	HOLD LONG
Summary: GILD maintains an uptrend with EMA above SMA and both rising, price holding above key support at 115.8 after pulling back from recent highs near 123.4, supported by positive oncology pipeline updates and no major bearish catalysts, justifying continuing the long position from 119.79 targeting resistance around 124....
2025-11-07	HOLD LONG
Summary: GILD's uptrend persists with EMA above SMA and both rising, price pulling back but holding above key support at 115.8 after recent highs, supported by positive oncology developments and no bearish catalysts, justifying holding the long position from 119.79 targeting resistance near 124....
2025-11-06	HOLD LONG
Summary: GILD remains in a strong uptrend with EMA above SMA, both rising, price above both, recent breakout to new highs on positive oncology pipeline news and no immediate bearish catalysts, supporting holding the existing long position from $119.79 four bars ago targeting further upside beyond 124 resistance....
2025-11-05	HOLD LONG
Summary: GILD maintains a strong uptrend with EMA above SMA, both rising, price above both, nearing resistance at 123-124 amid positive oncology developments and no immediate bearish catalysts, supporting holding the existing long position entered at $119.79 three bars ago....
2025-11-04	HOLD LONG
Summary: GILD continues in a strong uptrend with EMA above SMA, both rising and price above both, pushing towards resistance at 123-124 on post-earnings momentum, bolstered by positive oncology pipeline updates and no imminent bearish catalysts....
2025-11-03	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA, both rising and price above both, recent post-earnings momentum pushing towards resistance near 123-124, supported by strong oncology pipeline and no immediate bearish catalysts or events....
2025-10-31	BUY
Summary: GILD is in a clear uptrend with EMA above SMA, price above both and both rising, post-earnings bounce from support near 118 showing bullish momentum without immediate catalysts, supported by strong oncology pipeline and recent insider buys, targeting resistance near 123-124 over the next few weeks; re-entering soon after exit as earnings risk has passed with positive reaction, price rebounded above exit level, and no ongoing bearish factors....
2025-10-30	CASH
Summary: GILD's uptrend persists with EMA above SMA and price above both, but earnings today on 10/30/2025 warrant staying in cash to avoid potential volatility, especially after recent exit on 10/29/2025 for the same reason, with no compelling new catalysts for immediate re-entry....
2025-10-29	SOLD
Summary: GILD's technicals show a continuing uptrend with price above rising EMA and SMA, but exit the long position to avoid holding through earnings on 10/30/2025 since historical surprises and reactions fall short of criteria for low-volatility confidence....
2025-10-28	BUY
Summary: GILD is in a clear uptrend with EMA above SMA, price above both and both moving upward, recent pullback to support near 118 presenting a dip-buy opportunity ahead of low-volatility earnings on 10/30/2025, supported by strong pipeline momentum in HIV and oncology without major bearish news....
2025-10-27	CASH
Summary: GILD remains in cash due to upcoming earnings on 10/30/2025 within 3 days, preventing new long entry despite clear uptrend with EMA above SMA, price above both, and both rising, while no compelling short setup exists for this biotech stock....
2025-10-24	CASH
Summary: GILD's clear uptrend with EMA above SMA and price above both supports a long entry, but upcoming earnings on 10/30/2025 do not meet criteria for holding through given low historical surprises and reactions, conflicting with minimum 10-14 day hold, so remain in cash to avoid volatility....
2025-10-23	CASH
Summary: GILD's chart shows a clear uptrend with price above rising EMA and SMA, but earnings today warrant caution to avoid entry on the event day despite positive historical surprises, while no high-confidence dip setup exists at current highs near resistance....
2025-10-22	CASH
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, showing strong momentum from recent oncology pipeline advancements and positive earnings history, but upcoming earnings on 10/23/2025 warrant staying in cash to avoid pre-earnings entry risk despite meeting hold-through criteria....
2025-10-21	CASH
Summary: GILD's clear uptrend with price above EMA and SMA supports a long, but the potential doji star top at recent highs, upcoming earnings on 10/23/2025 despite meeting hold-through criteria, and historical patterns of post-breakout pullbacks from similar setups suggest avoiding entry to prevent repeating past losses....
2025-10-20	CASH
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, showing strong momentum from recent breakout above $120 on high volume, but upcoming earnings on 10/23/2025 warrant staying in cash to avoid entry right before the event despite positive historical reactions allowing potential holds if already positioned....
2025-10-17	CASH
Summary: GILD remains in cash as the current breakout at highs doesn't qualify as a dip in the established uptrend, with overbought RSI at 70.9 signaling caution and recent similar setups leading to pullbacks and losses in trade history....
2025-10-16	CASH
Summary: GILD's trend is unclear with EMA slightly below SMA and price above both, no volume capitulation, and upcoming earnings on 10/23/2025 warrant staying in cash to avoid low-confidence entry amid rangebound action near resistance. RSI at 58.2 is neutral, MACD positive at 1.18 with bullish histogram, but Slow STO K at 91.7 suggests overbought conditions, increasing risk of pullback. Support at 107.75 has held recently, while resistance at 119.96 looms overhead, creating a trading range where entering long risks buying near the top without confirmed uptrend (requires EMA > SMA and price > both)....
2025-10-15	CASH
Summary: GILD's technical trend is unclear with EMA slightly below SMA, tightly rangebound without clear direction or volume capitulation, warranting staying in cash to avoid low-confidence entries amid recent volatility and no compelling catalysts. There's no recent volume capitulation flagged, and while price has bounced from supports like 107.75 recently, the lack of a defined uptrend prevents buying dips. MACD is positive at 1.1498 above its signal line of 0.4714, suggesting some bullish momentum, but RSI at 60.8 is neutral, and Slow STO K/D at 93/83 shows overbought conditions that could lead to pullbacks. Historical simulations from similar setups in the last 6 months, like the post-earnings breakout in August followed by a pullback below averages, show a win rate below 50% for longs entered without clear trends, often resulting in whipsaws as seen in the September trades that ended in losses....
2025-10-14	CASH
Summary: GILD's technicals show an unclear trend with EMA slightly below SMA and price above both, avoiding new entries, while near resistance at 119.96 and upcoming earnings on 10/23/2025 warrant caution despite positive earnings history allowing potential long holds....
2025-10-13	CASH
Summary: GILD's technicals show an unclear trend with EMA below SMA despite price above both, near resistance at 119.96 without strong bullish confirmation, and upcoming earnings on 10/23/2025 warrant staying in cash to avoid low-confidence entry....
2025-10-10	CASH
Summary: GILD's technicals show an unclear trend with EMA slightly below SMA and both tightly rangebound without volume capitulation, warranting staying in cash to avoid low-confidence entries amid recent volatility and upcoming earnings....
2025-10-09	CASH
Summary: GILD's trend is unclear with EMA below SMA despite price above both, no volume capitulation, and frequent crossings in the past month, making new entries risky amid proximity to resistance at 119.96 and upcoming earnings on 10/23/2025....
2025-10-08	CASH
Summary: GILD's technical trend is unclear with EMA below SMA but price above both, recent crossings indicating choppiness, no volume capitulation, and as a biotech stock we avoid shorting, so stay in cash to wait for a clearer high-confidence setup....
2025-10-07	CASH
Summary: GILD's trend is unclear with EMA below SMA in a tight range and no volume capitulation, preventing new entries while price sits near recent highs without strong bullish confirmation....
2025-10-06	CASH
Summary: GILD's technicals show an unclear trend with EMA below SMA, price between them, frequent crossings in the past month without volume capitulation, avoiding new entries despite some positive pipeline news, while staying opportunistic for clearer setups. Support at 107.75 has held in prior tests, but the lack of a defined trend and absence of capitulation signals make it risky to enter long here, especially as we're not chasing into resistance or buying unconfirmed dips....
2025-10-03	CASH
Summary: GILD is in a downtrend with EMA below SMA and price below both, lacking volume capitulation for a long entry, while shorting biotech stocks is avoided due to potential news-driven spikes, so staying in cash until a clearer uptrend emerges....
2025-10-02	CASH
Summary: GILD's unclear trend with EMA below SMA, price below both, frequent crossings without volume capitulation, combined with recent downtrend dips, no strong catalysts, and biotech risks warrant staying in cash to avoid poor entries after prior losses....
2025-10-01	CASH
Summary: GILD is in a downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and as a biotech stock it can't be shorted, so stay in cash awaiting a clearer setup....
2025-09-30	CASH
Summary: GILD's current downtrend with EMA below SMA and price below both, no volume capitulation, and biotech nature prohibiting shorts make staying in cash the best move to await a clearer high-confidence setup....
2025-09-29	CASH
Summary: GILD remains in a downtrend with EMA below SMA and price below both, no volume capitulation, and recent long trades resulted in losses, so staying in cash avoids poor entry while awaiting clearer bullish signals....
2025-09-26	CASH
Summary: GILD's technicals show an unclear trend with EMA below SMA, price below both, and moving averages tightly rangebound without clear direction, warranting staying in cash to avoid low-confidence entries....
2025-09-25	CASH
Summary: GILD's trend is unclear with EMA below SMA, price below both, frequent price crossings of moving averages in the past month without volume capitulation, ruling out new entries despite support near 111 and no immediate catalysts....
2025-09-24	CASH
Summary: GILD's technicals indicate an unclear trend with EMA slightly below SMA and price below both, no recent volume capitulation, combined with recent trade history of losses on longs and its biotech nature prone to sudden news spikes, making cash the safest position to avoid poor entries....
2025-09-23	CASH
Summary: GILD's trend is unclear with EMA slightly below SMA, tightly rangebound averages, and price crossing them twice recently without volume capitulation, warranting no new entry despite a recent bounce to 114.98 and neutral news on pipeline progress....
2025-09-22	CASH
Summary: GILD's trend is unclear with EMA and SMA tightly converged and price below both, recent trades resulted in losses from failed bounces, and no compelling catalysts or volume support for a new entry, favoring cash to await clearer setups....
2025-09-19	CASH
Summary: GILD's clear uptrend with EMA above SMA and price above both suggests potential for longs, but recent price at 114.32 is not a dip, MACD shows bearish crossover, no volume capitulation for stronger entry, and past trades indicate caution after quick losses from chasing non-dips near resistance....
2025-09-18	CASH
Summary: GILD's trend is unclear with EMA slightly above SMA but price below both, tightly rangebound averages without clear direction, and recent trade history shows losses in similar setups, warranting caution to avoid new entry....
2025-09-17	CASH
Summary: GILD's trend is unclear with EMA slightly above SMA but price below both, recent losses from failed longs, no volume capitulation or compelling catalysts for entry, so stay in cash awaiting better setup....
2025-09-16	CASH
Summary: GILD's technicals show an unclear trend with price below both EMA and SMA, no volume capitulation, and recent long exit on 9/15 due to weakening momentum, making new entries inadvisable without stronger bullish signals....
2025-09-15	SOLD
Summary: GILD's price has fallen below both EMA and SMA in an unclear trend with no volume capitulation, testing support near 112 without bullish reversal, warranting exit from the long position to preserve capital amid weakening momentum....
2025-09-12	HOLD LONG
Summary: GILD maintains a clear uptrend with EMA above SMA and price above both, recent price action rebounding from support near 112-114 towards resistance at 120, supported by positive pipeline developments and no immediate catalysts for exit....
2025-09-11	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, rebounding strongly from support near 112-114 towards resistance at 120, bolstered by positive oncology pipeline momentum and no near-term catalysts warranting an exit....
2025-09-10	HOLD LONG
Summary: GILD maintains a clear uptrend with EMA above SMA and price above both, holding above key support near 112-114 after a minor pullback, supported by positive oncology pipeline updates and no imminent catalysts or breakdowns suggesting an exit, targeting resistance around 120....
2025-09-09	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, holding above key support near 112-114 after a recent bounce, with no immediate catalysts or trend breakdowns warranting an exit yet, targeting resistance around 120....
2025-09-08	BUY
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, recent bounce from support near 112 showing bullish momentum, supported by positive pipeline developments in oncology and no near-term earnings risk, targeting resistance at 120 over the next few weeks....
2025-09-05	CASH
Summary: GILD's chart shows a clear uptrend with price above EMA and SMA after a recent bounce from 112 support, but lacking strong catalysts, unusual options activity, or volume confirmation for a high-confidence long entry so soon after exiting at a lower price on 9/2 due to unclear trend then, now clarified but with MACD still bearish and near 116-120 resistance range....
2025-09-04	CASH
Summary: GILD's trend is unclear with price below both EMA and SMA, no recent volume capitulation to signal a reversal, and a fresh exit from a losing long position on 9/2/2025 due to similar pullback conditions, making new entries risky without stronger bullish confirmation....
2025-09-03	CASH
Summary: GILD's trend is unclear with EMA above SMA but price below both, no volume capitulation, and recent exit on 9/2 at $112.71 due to similar conditions, so stay in cash to avoid low-confidence entry....
2025-09-02	SOLD
Summary: Exit existing long in GILD as price remains below both EMA and SMA in an unclear trend, with no immediate catalysts or volume support for rebound, and recent pullback testing supports without clear bullish reversal....
2025-08-29	HOLD LONG
Summary: Hold existing long in GILD despite pullback below MAs, as EMA remains above SMA without clear downtrend, price above key support at 107.75, no volume capitulation signaling reversal, and biotech catalysts like potential drug approvals could drive rebound over weeks....
2025-08-28	HOLD LONG
Summary: Hold existing long in GILD as the uptrend remains intact with EMA above SMA, price near key support at 107.75 without breakdown, and biotech sector potential for positive catalysts outweighs the current pullback....
2025-08-27	HOLD LONG
Summary: Hold existing long in GILD as technicals show EMA above SMA with price above SMA and key support at 107.75 intact, no volume capitulation or breakdown, while biotech upside from potential news outweighs current pullback....
2025-08-26	HOLD LONG
Summary: Hold existing long position in GILD as technicals show unclear trend with price above SMA and key supports like 107.75, no volume capitulation or breakdown signaling exit, while biotech nature offers upside from potential positive news catalysts. Price is respecting rising support trendlines around $111.32 and hasn't breached key horizontal supports at $107.75 (recently tested with bounces), suggesting potential for recovery rather than a sustained downtrend, especially without volume capitulation flags in the data....
2025-08-25	HOLD LONG
Summary: GILD's technicals show an unclear trend with price below EMA but above SMA and key supports like 107.75, no volume capitulation or breakdown, so hold the existing long position entered at $120.14 amid recent pullback without strong exit signals, while biotech nature limits downside risks from sudden positive news. Volume has been moderate, and indicators like RSI at 46.65 suggest neither overbought nor deeply oversold, while MACD is positive but weakening (line 1.13 > signal 1.65? Wait, data shows MACD 1.1288, MACD_EMA 1.6507, actually converging bearishly). Bollinger Bands are widening slightly, with price near the middle, hinting at potential volatility but no immediate breakdown. Visuals show a rising support trendline around $111, last tested recently, providing a buffer. Simulating past patterns, similar pullbacks in early 2025 (e.g., post-February peaks) often found support and rebounded without capitulating, with a >50% win rate on holds through such dips when above key levels; for instance, the May dip to $96 bounced back to $112, avoiding whipsaw by not exiting prematurely. Avoiding past mistakes like the pre-earnings exit in August that locked gains but missed the breakout, here the position is only 8 bars in, below the 10-14 day minimum, so patience is key absent a sustained break below supports....
2025-08-22	HOLD LONG
Summary: GILD remains in an uptrend with EMA above SMA, price recently dipping slightly below EMA but holding above key supports like 107.75 without breakdowns, and the position requires longer hold absent strong exit signals....
2025-08-21	HOLD LONG
Summary: GILD maintains a clear uptrend with EMA above SMA and price above both, no breakdowns below key supports like 107.75, and the position is only 6 bars in requiring a longer hold absent strong exit signals....
2025-08-20	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, showing resilience after a minor pullback from recent highs, with no breakdowns, catalysts, or violations of key supports warranting an exit from the existing long position entered 5 bars ago at $120.14....
2025-08-19	HOLD LONG
Summary: GILD maintains a clear uptrend with EMA above SMA and price above both, showing post-earnings resilience despite a minor pullback, with no breakdowns or catalysts warranting an early exit from the long position entered 4 bars ago at $120.14....
2025-08-18	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, holding post-earnings momentum despite a minor pullback to 118.35, with no breakdowns or catalysts justifying an exit after only three bars....
2025-08-15	HOLD LONG
Summary: GILD continues in a solid uptrend with EMA above SMA and price above both, maintaining the post-earnings breakout momentum around $120 despite a minor pullback, with no immediate catalysts or breakdowns warranting an early exit after just two bars....
2025-08-14	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, holding the post-earnings breakout level around $120 on decent volume, suggesting continued momentum over the next few weeks despite a minor dip today....
2025-08-13	BUY
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, recent post-earnings breakout above $120 resistance on high volume signals strong momentum for further gains over the next few weeks....
2025-08-12	CASH
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, but it's near resistance at 119.96 after a sharp post-earnings rally, so staying in cash to avoid buying at the top and wait for a dip or breakout confirmation for a high-confidence long entry....
2025-08-11	CASH
Summary: GILD is in a clear uptrend with EMA above SMA and price above both, but the current price at 120.47 is breaking recent resistance at 119.96 on high volume post-earnings, yet it's not a dip entry and risks pullback after the sharp run-up, so staying in cash avoids buying at potential top while waiting for a better opportunistic setup....
2025-08-08	CASH
Summary: GILD is in an uptrend with EMA above SMA and price above both, but the recent post-earnings gap-up to near resistance at $119.96 on 8/8/2025 provides a poor entry for a new long position without a dip, especially after our recent exit at $113.18, so staying in cash avoids buying at the top and allows waiting for a better pullback opportunity....
2025-08-07	CASH
Summary: GILD's technicals show an unclear trend with price dipping below both EMA and SMA on earnings day, warranting staying in cash to avoid volatility....
2025-08-06	CASH
Summary: GILD's technicals show an unclear trend with price below both EMA and SMA despite EMA above SMA, no volume capitulation, and earnings tomorrow on August 7, 2025, making entry too risky. Fundamentals from recent web info highlight positive developments like a potential game-changer in lung cancer treatment and stock price performance, but I never go against technicals for news or earningsâ€”historically, GILD has shown sharp moves post-earnings, as seen in past spikes and drops, so staying in cash avoids potential whipsaw. Simulation of similar pre-earnings dips in the last year often led to false signals with <50% win rate if entered, like the November 2024 drop after a range, reinforcing patience here. No other major event catalysts noted beyond the Q2 earnings on August 7, 2025. If post-earnings shows strength with volume and trend confirmation, that could set up a future buy, but for now, opportunistically wait for better setup.
2025-08-05	CASH
Summary: GILD's uptrend remains intact with EMA above SMA and price above both, but upcoming Q2 earnings on August 7, 2025, warrant staying in cash to avoid potential volatility from an expected earnings drop, despite some bullish analyst sentiment....
2025-08-04	CASH
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, but upcoming Q2 earnings on August 7, 2025, combined with analyst forecasts for a single-digit earnings drop and no compelling positive catalysts, warrant staying in cash to avoid potential volatility....
2025-08-01	SOLD
Summary: GILD's uptrend persists with EMA above SMA and price above both, but upcoming Q2 earnings on August 7, 2025, combined with expected earnings drop, ongoing investigation, and no compelling positive catalyst to justify holding through volatility, warrant exiting the long position near recent highs to lock in gains....
2025-07-31	HOLD LONG
Summary: GILD continues its uptrend with EMA above SMA, price above both, positive MACD, and bullish catalysts like lung cancer study advancements and analyst upgrades outweighing the expected earnings drop, supporting holding long toward resistance near 118 while monitoring Q2 earnings on August 7, 2025....
2025-07-30	HOLD LONG
Summary: GILD maintains a strong uptrend with EMA above SMA, price above both, positive MACD, and bullish fundamentals including recent analyst upgrades, HIV pipeline advancements, and promising lung cancer study results, supporting holding the long position toward resistance near 118 while monitoring the upcoming Q2 earnings on August 7, 2025....
2025-07-29	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA, price above both, positive MACD, and supportive fundamentals like bullish analyst ratings and HIV pipeline progress, holding through to potential resistance near 118 while monitoring earnings on August 7, 2025....
2025-07-28	HOLD LONG
Summary: GILD remains in a solid uptrend with price above EMA and SMA, supported by positive news on HIV and oncology advancements, and no immediate catalysts to exit the long position entered at $108.22 six bars ago targeting 114 resistance....
2025-07-25	HOLD LONG
Summary: GILD's uptrend remains strong with EMA above SMA and price above both, bolstered by positive CHMP recommendation for lenacapavir boosting shares 3% today, and Needham's upgrade to Buy with $133 target, suggesting further upside potential despite upcoming earnings....
2025-07-24	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA, price above both, recent bounce from rising support at 102.84 holding firm, positive MACD, and no immediate catalysts to invalidate the long position targeting 114 resistance, supported by strong pipelines despite expected Q2 earnings drop. ...
2025-07-23	HOLD LONG
Summary: GILD remains in a strong uptrend with price above both EMA and SMA, recent closes pushing towards 114 resistance on positive momentum, supported by solid Q1 results and HIV pipeline progress, despite analyst forecasts of a slight Q2 earnings drop....
2025-07-22	HOLD LONG
Summary: GILD remains in a clear uptrend with EMA above SMA and price above both, supported by recent volume capitulation, positive pipeline news, and no immediate catalysts, justifying holding the long position entered at $108.22 for potential upside to $114 resistance....
2025-07-21	HOLD LONG
Summary: GILD's long position remains valid with price holding above key support at 102.84 amid an unclear but not invalidated uptrend, positive MACD, and recent bullish news on oncology pipeline advancements suggesting continued upside to 114 resistance over the next few weeks....
2025-07-18	BUY
Summary: GILD shows a bullish technical setup with price bouncing from rising support at 102.84, positive MACD crossover, oversold STO, and recent high-volume upticks, supported by strong fundamentals in HIV and oncology pipelines, suggesting upside to 114 resistance over the next few weeks....